Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Philadelphia ,Pennsylvania ,Christen Baglaneas ,Tim Clackson ,Suzanne George ,David Kerstein ,Josh Rappaport ,Nasdaq ,Theseus Pharmaceuticals Inc ,Sarcoma Center ,Exchange Commission ,Dana Farber Cancer Institute ,Theseus Pharmaceuticals ,Clinical Development Plan ,Corporate Communications Investor Relations ,Predictive Resistance Assay ,Chief Executive Officer ,Associate Division Chief ,Chief Medical Officer ,Trial Background ,Clinical Development ,Theseu Form ,Quarterly Reports ,Corporate Communications ,